Predictors of bronchopulmonary dysplasia or death in premature infants with a patent ductus arteriosus

Pediatric Research

Volumn 75, Issue 4, 2014, Pages 570-575

  Chock, Valerie Y ^a   Punn, Rajesh ^a   Oza, Anushri ^a   Benitz, William E ^a   Van Meurs, Krisa P ^a   Whittemore, Alice S ^a   Behzadian, Fariborz ^a   Silverman, Norman H ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN;

ARTICLE; BIRTH WEIGHT; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PRIORITY JOURNAL;

BRONCHOPULMONARY DYSPLASIA; DUCTUS ARTERIOSUS, PATENT; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE;

EID: 84896459977     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2013.253     Document Type: Article

References (34)

1. Clyman RI, Couto J, Murphy GM. Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all? Semin Perinatol 2012;36:123-9.
2. Bancalari E, Claure N, Sosenko IR. Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and defnition. Semin Neonatol 2003;8:63-71.
3. Gonzalez A, Sosenko IR, Chandar J, Hummler H, Claure N, Bancalari E. Infuence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr 1996;128:470-8.
4. Marshall DD, Kotelchuck M, Young TE, Bose CL, Kruyer L, O'Shea TM. Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association. Pediatrics 1999;104:1345-50.
5. Oh W, Poindexter BB, Perritt R, et al.; Neonatal Research Network. Association between fuid intake and weight loss during the frst ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr 2005;147:786-90.
6. Nemerofsky SL, Parravicini E, Bateman D, Kleinman C, Polin RA, Lorenz JM. The ductus arteriosus rarely requires treatment in infants > 1000 grams. Am J Perinatol 2008;25:661-6.
7. Chorne N, Jegatheesan P, Lin E, Shi R, Clyman RI. Risk factors for persistent ductus arteriosus patency during indomethacin treatment. J Pediatr 2007;151:629-34.
8. Lemmers PM, Toet MC, van Bel F. Impact of patent ductus arteriosus and subsequent therapy with indomethacin on cerebral oxygenation in pre-term infants. Pediatrics 2008;121:142-7.
9. Pezzati M, Vangi V, Biagiotti R, Bertini G, Cianciulli D, Rubaltelli F F. Effects of indomethacin and ibuprofen on mesenteric and renal blood fow in preterm infants with patent ductus arteriosus. J Pediatr 1999;135:733-8.
10. Pryds O, Greisen G, Johansen KH. Indomethacin and cerebral blood fow in premature infants treated for patent ductus arteriosus. Eur J Pediatr 1988;147:315-6.
11. Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufciency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004;114:1649-57.
12. Rheinlaender C, Helfenstein D, Walch E, Berns M, Obladen M, Koehne P. Total serum bilirubin levels during cyclooxygenase inhibitor treatment for patent ductus arteriosus in preterm infants. Acta Paediatr 2009;98: 36-42.
13. Clement WA, El-Hakim H, Phillipos EZ, Coté JJ. Unilateral vocal cord paralysis following patent ductus arteriosus ligation in extremely low-birth-weight infants. Arch Otolaryngol Head Neck Surg 2008;134: 28-33.
14. Noori S, Friedlich P, Seri I, Wong P. Changes in myocardial function and hemodynamics afer ligation of the ductus arteriosus in preterm infants. J Pediatr 2007;150:597-602.
15. Benitz WE. Treatment of persistent patent ductus arteriosus in pre-term infants: time to accept the null hypothesis? J Perinatol 2010;30: 241-52.
16. Sosenko IR, Fajardo MF, Claure N, Bancalari E. Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. J Pediatr 2012;160:929-35.e1.
17. Benitz WE. Learning to live with patency of the ductus arteriosus in pre-term infants. J Perinatol 2011;31:Suppl 1:S42-8.
18. Ambalavanan N, Van Meurs K P, Perritt R, et al.; NICHD Neonatal Research Network, Bethesda, MD. Predictors of death or bronchopul-monary dysplasia in preterm infants with respiratory failure. J Perinatol 2008;28:420-6.
19. Sinkin RA, Cox C, Phelps DL. Predicting risk for bronchopulmonary dys-plasia: selection criteria for clinical trials. Pediatrics 1990;86:728-36.
20. Madan JC, Kendrick D, Hagadorn JI, Frantz ID 3rd; National Institute of Child Health and Human Development Neonatal Research Network. Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome. Pediatrics 2009;123:674-81.
21. Chorne N, Leonard C, Piecuch R, Clyman RI. Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics 2007;119:1165-74.
22. Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanarof A; Trial of Indomethacin Prophylaxis in Preterms Investigators. Neurosensory impairment afer surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr 2007;150:229-34, 234.e1.
23. Kaempf J W, Wu YX, Kaempf AJ, Kaempf AM, Wang L, Grunkemeier G. What happens when the patent ductus arteriosus is treated less aggressively in very low birth weight infants? J Perinatol 2012;32:344-8.
24. Kwinta P, Rudzinski A, Kruczek P, Kordon Z, Pietrzyk JJ. Can early echo-cardiographic fndings predict patent ductus arteriosus? Neonatology 2009;95:141-8.
25. Ramos FG, Rosenfeld CR, Roy L, Koch J, Ramaciotti C. Echocardio-graphic predictors of symptomatic patent ductus arteriosus in extremely-low-birth-weight preterm neonates. J Perinatol 2010;30:535-9.
26. Su BH, Peng CT, Tsai CH. Echocardiographic fow pattern of patent duc-tus arteriosus: a guide to indomethacin treatment in premature infants. Arch Dis Child Fetal Neonatal Ed 1999;81:F197-200.
27. El-Khufash AF, McNamara PJ. The patent ductus arteriosus ligation decision. J Pediatr 2011;158:1037-8; author reply 1038-9.
28. Sehgal A, Paul E, Menahem S. Functional echocardiography in staging for ductal disease severity: role in predicting outcomes. Eur J Pediatr 2013;172:179-84.
29. McNamara PJ, Sehgal A. Towards rational management of the patent duc-tus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed 2007;92:F424-7.
30. Chen S, Tacy T, Clyman R. How useful are B-type natriuretic peptide measurements for monitoring changes in patent ductus arteriosus shunt magnitude? J Perinatol 2010;30:780-5.
31. Reller MD, Lorenz JM, Kotagal UR, Meyer RA, Kaplan S. Hemodynami-cally signifcant PDA: an echocardiographic and clinical assessment of incidence, natural history, and outcome in very low birth weight infants maintained in negative fuid balance. Pediatr Cardiol 1985;6:17-23.
32. Silverman NH, Lewis AB, Heymann MA, Rudolph AM. Echocardio-graphic assessment of ductus arteriosus shunt in premature infants. Circulation 1974;50:821-5.
33. Su BH, Watanabe T, Shimizu M, Yanagisawa M. Echocardiographic assessment of patent ductus arteriosus shunt fow pattern in premature infants. Arch Dis Child Fetal Neonatal Ed 1997;77:F36-40.
34. Serwer GA, Armstrong BE, Anderson PA. Continuous wave Doppler ultrasonographic quantitation of patent ductus arteriosus fow. J Pediatr 1982;100:297-9.